Considerations for Treatment Sequencing in LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes (LR-MDS) include limited access to newer therapies, patient-specific factors, and treatment sequencing complexities, and explores strategies to address these barriers, such as improving health care access, optimizing patient selection, and enhancing treatment guidelines.
Video content above is prompted by the following:
What are existing challenges or barriers with regard to treatment choices, and how can they be addressed?
Recent Videos
Related Content
